Financial Performance - As of December 31, 2025, the Contract Asset related to service concession agreements amounted to R$14,430,593 thousand in the individual financial statements and R$14,437,363 thousand in the consolidated financial statements[13]. - Revenue from sanitation services for the year ended December 31, 2025, includes unbilled revenue and is recognized based on water consumption, with significant judgment required for estimates[18]. - The individual and consolidated financial statements present fairly the Company's financial position and performance in accordance with Brazilian accounting practices and IFRS[9]. - In 2025, Sabesp achieved R$ 37.6 billion in net revenue, a 4% increase compared to 2024, while net income decreased by 12% to R$ 8.5 billion, primarily due to a one-time gain of R$ 5.5 billion in 2024 from financial asset bifurcation[58]. - Sabesp's net revenue from sanitation services rose by 2.2% year-over-year to R$ 22.2 billion, driven by a 2.4% increase in billed volume and a 3.7% increase in net price[60]. - The Company reported a profit for the period of R$ 8.46 billion in 2025, compared to R$ 9.58 billion in 2024, reflecting a decrease of 11.7%[77]. - Total comprehensive income for the period fell to R$ 8,299,798 in 2025, down from R$ 9,713,540 in 2024, a decrease of about 14.5%[79]. - SABESP's consolidated revenue for 2025 reached R$ 40,351,971 thousand, an increase of 5.0% compared to R$ 38,383,655 thousand in 2024[84]. Audit and Compliance - The audit procedures included detailed testing of high transaction volume suppliers and field inspections of ongoing construction works to verify asset existence[16]. - The audit included correlation tests on journal entries among revenue, accounts receivable, and cash accounts to ensure accuracy[19]. - The audit addressed key matters such as the measurement of unbilled revenue and the recognition of contract assets, which are significant to the financial statements[11]. - The executive board is responsible for the preparation and fair presentation of the financial statements, ensuring they are free from material misstatement[26]. - The Company is required to assess its ability to continue as a going concern and disclose relevant matters accordingly[27]. - The Company’s financial statements for the year ended December 31, 2024, were audited by another independent auditor, who issued an unmodified audit report[21]. Investments and Capital Expenditures - The company invested R$ 15.2 billion in water supply and sewage infrastructure in 2025, exceeding all U-Factor targets for the 2024-2025 cycle, including 152% of the Water Units target and 134% of the Sewage Treatment target[37]. - Sabesp's capital expenditures (capex) increased by 120% year-over-year to R$ 15.2 billion, with plans for approximately R$ 70 billion in investments by 2029 to achieve universalization of services[63]. - The company plans to add at least 12.8 m³/s of water capacity by 2030 through various projects, with an estimated capital expenditure of R$ 8.2 billion[55]. Debt and Equity - As of December 31, 2025, the Company's net debt reached R$ 27.77 billion, an increase from R$ 19.88 billion in 2024, reflecting a net debt/Adjusted EBITDA ratio of 2.2x[67][68]. - The Company's total equity increased by 15% year-over-year, reaching R$ 42.4 billion as of December 31, 2025, driven by retained earnings[68]. - The Leverage Ratio rose to 40% in 2025 from 35% in 2024, indicating a 5 percentage point increase year-over-year[67]. - Total liabilities increased to R$ 61.80 billion in 2025 from R$ 44.05 billion in 2024, reflecting the Company's growing financial obligations[75]. - Total borrowings and financing as of December 31, 2025, amounted to R$ 40,301,603, an increase from R$ 25,258,297 in 2024, reflecting a growth of 59.7%[138]. - Net debt increased to R$ 28,037,975 in 2025 from R$ 19,883,064 in 2024, representing a rise of 40.5%[138]. - Total equity as of December 31, 2025, was R$ 42,401,124, up from R$ 36,928,054 in 2024, indicating an increase of 14.1%[138]. Cash Flow and Liquidity - Cash generated from operations increased to R$ 13,426,380 in 2025 compared to R$ 11,130,885 in 2024, reflecting a growth of approximately 20.6%[82]. - Net cash generated from operating activities rose to R$ 8,216,566 in 2025, up from R$ 7,393,824 in 2024, an increase of about 11.1%[82]. - Cash and cash equivalents at the end of the year reached R$ 4,569,998 in 2025, up from R$ 1,681,204 in 2024, marking an increase of about 172.5%[82]. - The company recorded a significant increase in borrowings and financing, totaling R$ 18,462,151 in 2025, compared to R$ 6,870,754 in 2024[82]. - Interest paid increased to R$ 2,696,320 in 2025 from R$ 1,976,694 in 2024, reflecting a rise of approximately 36.4%[82]. - The company has been managing liquidity risk by ensuring sufficient cash flow from operating activities and maintaining access to local and international capital markets[129]. Operational Efficiency - The company reduced administrative costs and expenses by 13.8% to R$ 11.2 billion, with significant reductions in general expenses (-54.5%) and personnel costs (-9.9%) due to a 13% workforce reduction[62]. - Sabesp's workforce optimization resulted in a reduction to 9,204 employees, reflecting a strategic focus on efficiency and governance[39]. - The company modernized its metering infrastructure by installing approximately 1.5 million new meters and secured a contract for the world's largest smart metering project, involving 4.4 million IoT-enabled meters by 2029[38]. Environmental and Social Responsibility - Sabesp formalized a decarbonization roadmap targeting a 41% reduction in greenhouse gas emissions by 2035, while improving its CDP Climate score from "C" to "B"[40]. - The company is engaged in expanding its operations beyond São Paulo, potentially entering new markets for drainage, urban cleaning, and solid waste handling[87]. Financial Risk Management - The company has established a financial risk management policy to mitigate exposure to market variables affecting assets and liabilities[133]. - The maximum exposure to credit risk as of December 31, 2025 was related to cash and cash equivalents, financial investments, and accounts receivable, with all investments made with institutions rated AAA[126][128]. - The company managed its interest rate risk by entering into derivative financial instruments, with a sensitivity analysis indicating that a 1 percentage point change in interest rates would affect consolidated profit before taxes by R$ 339,248 for the year ended December 31, 2025[121].

Financial Performance - Revenues for the three months ended January 31, 2026, were $16,890,000, a decrease of 10.9% compared to $18,927,000 for the same period in 2025[14] - Gross margin for the nine months ended January 31, 2026, was $18,244,000, down 19.4% from $22,603,000 in the prior year[14] - Net income for the nine months ended January 31, 2026, was $4,002,000, a significant decline of 80.5% compared to $20,489,000 for the same period in 2025[14] - Total operating income for the three months ended January 31, 2026, was $1.27 million, a decrease of 63.4% compared to $3.47 million in 2025[44] - The net income margin for the three months ended January 31, 2026, was 9.3%, a significant decrease from 81.4% in the same period of 2025[72] - Operating income for the three months ended January 31, 2026, was 7.5%, down from 18.3% in the same period of 2025[72] - For the nine months ended January 31, 2026, consolidated revenues were $47.83 million, a decrease of 4.0% from $49.83 million in the same period of the prior year[74] Assets and Liabilities - Total current assets as of January 31, 2026, were $52,554,000, slightly down from $53,106,000 as of April 30, 2025[12] - Total liabilities decreased to $33,949,000 as of January 31, 2026, from $38,117,000 as of April 30, 2025, reflecting a reduction of 10.4%[12] - Total identifiable assets as of January 31, 2026, were $94.19 million, a slight increase from $93.74 million as of April 30, 2025[47] - The total lease liabilities as of January 31, 2026, were $8.13 million, down from $8.76 million as of April 30, 2025[36] - As of January 31, 2026, the company's working capital was approximately $32.4 million, with a current ratio of 2.6 to 1, up from 2.3 to 1 as of April 30, 2025[90] Cash Flow - Cash and cash equivalents at the end of the period were $1,478,000, down from $6,871,000 at the end of the same period in 2025, indicating a decrease of 78.5%[17] - The company reported a net cash used in operating activities of $779,000 for the nine months ended January 31, 2026, compared to $1,273,000 for the same period in 2025[17] - Net cash used in operating activities for the nine months ended January 31, 2026, was approximately $0.8 million, compared to $1.3 million for the same period in 2025, primarily due to timing of billings and a decrease in net income[91] - Net cash used in investing activities for the nine months ended January 31, 2026, was approximately $2.3 million, up from $1.2 million in 2025, all related to capital expenditures[92] - Net cash used in financing activities for the nine months ended January 31, 2026, was $1.6 million, primarily for the purchase of treasury stock, compared to $9.9 million in 2025, which included a special cash dividend payout[93] Research and Development - Research and development expenses for the nine months ended January 31, 2026, were $4,095,000, a decrease of 9.7% compared to $4,536,000 in the previous year[14] - Research and development (R&D) expenses increased by 22.8% to $1.76 million for the three months ended January 31, 2026, compared to $1.44 million in the same period of the prior year[81] - The company plans to continue investing in R&D for space applications and anticipates securing additional customer funding for these activities[96] Stockholder Equity and Dividends - The total stockholders' equity increased to $60,243,000 as of January 31, 2026, from $55,620,000 as of April 30, 2025, representing an increase of 8.9%[12] - The company did not pay any dividends during the nine months ended January 31, 2026, compared to $9,567,000 in dividends paid in the same period of 2025[17] - The company declared a special cash dividend of $1.00 per share, totaling approximately $9.6 million, paid on August 29, 2024[27] Segment Performance - FEI-NY segment revenues decreased to $12.25 million for the three months ended January 31, 2026, down 15.2% from $14.46 million in 2025[44] - FEI-Zyfer segment revenues increased to $6.98 million for the three months ended January 31, 2026, up 38.8% from $5.03 million in 2025[44] - Revenues from commercial and U.S. Government communication satellite programs accounted for approximately 25% of consolidated revenues for the three months ended January 31, 2026, down from 59% in the prior fiscal year[76] Other Financial Metrics - The effective tax rate for the three months ended January 31, 2026, was an income tax benefit of 8.84% on pretax income of $1.4 million, compared to 330.2% on pretax income of $3.6 million in the prior year[88] - The estimated annual effective tax rate for the fiscal year ending April 30, 2026, is 25.10%[85] - The company recorded an income tax benefit of $127,246 for the three months ended January 31, 2026, compared to an income tax benefit of $11.8 million in the same period of the prior year[86] Share Repurchase and Liquidity - The company has authorized a new share repurchase program of $20.0 million, replacing the previous authorization with approximately $0.6 million remaining[94] - During the three months ended January 31, 2026, the company repurchased 12,260 shares at a weighted average price of $50.22 per share[95] - The company believes its liquidity is adequate to meet short-term operating and investment needs through at least March 17, 2027[99]

Financial Performance - Revenue for Q4 2025 reached $70 million, with a year-to-date (YTD) growth of 23% compared to the previous year[33] - Adjusted EBITDA for Q4 2025 was $16 million, reflecting a compound annual growth rate (CAGR) of 31% from 2020 to 2025[22] - Revenue increased by 146% from $52M in 2020 to $128M by LTM 12/31/25[58] - NOI rose by 182% from $22M in 2020 to an expected $62M by LTM 12/31/25[58] - Adjusted EBITDA for Q4 2025 is projected at $8,099K, compared to $3,445K in 2020[101] Portfolio and Asset Management - The stabilized commercial managed portfolio is 93% leased, with 602,000 square feet leased YTD and 410,000 square feet leased in Q4 alone[33] - The commercial portfolio's weighted average lease term is 8.7 years, with a total of 1.74 million square feet leased since 2020[56] - The average annual supplemental asset management fee income from FY 2022-2025 is $4.4 million, with incentive fees averaging $3.4 million per year[24] Growth and Expansion - ParkX subsidiary revenue increased by 123% year-over-year, securing 45 new contracts in FY25, including 19 in Q4[33] - Residential units increased from 1,123 in 2020 to 1,638 by Q4 2025, a growth of 46%[58] - Leased percentage for residential properties improved from 73% in 2020 to 93% by Q4 2025, a 20% increase[58] - Commercial square footage expanded from 1.8M sqft in 2020 to 2.4M sqft by Q4 2025, a 33% increase[58] - The number of parking garages under ParkX increased from 3 in 2020 to 34 by Q4 2025, a growth of 1033%[58] - Total parking spaces increased from 8,000 in 2020 to 25,902 by Q4 2025, a 224% increase[58] - The total under construction and development pipeline amounts to approximately 4,648,786 sqft, including 2,745 units and 240 hotel keys[76] Strategic Initiatives - Comstock's Institutional Venture Platform aims to co-invest in real estate opportunities, enhancing growth potential through strategic partnerships[35] - The Data Center Platform was launched to capitalize on the growing demand for data center capacity, with a joint venture established for large-scale data center development[45] - Significant assets under construction include the BLVD Haley, a 419-unit luxury residential tower, scheduled for full delivery by Q2 2026[33] Stock Performance - Comstock's stock price increased by 193% from 2020 to December 31, 2025, outperforming peers[32] - The current AUM is over $2.5 billion, with a full build-out AUM projected to exceed $5 billion[94]

Financial Performance - Q4 2025 revenue was $28.2 million, down from $36.2 million in Q4 2024, with a gross margin of 43.6% compared to 52.8% in Q4 2024[4] - Net income for Q4 2025 was $5.3 million, or 18.8%, compared to $6.9 million, or 19.1%, in Q4 2024, reflecting operational discipline[4] - Full year revenue increased to $134.8 million in 2025 from $125.9 million in 2024, with advertising revenue dropping to 64% of total revenue from 74%[4] - Full year gross margin expanded to 50.7% in 2025 from 44.2% in 2024, indicating improved structural efficiency[4] - Net income for 2025 was $124.9 million, including $96.3 million from discontinued operations, compared to a net loss of $100.7 million in 2024[4] - Adjusted EBITDA for 2025 improved to $51.5 million, or 38.2%, compared to $27.0 million, or 21.4%, in 2024, signaling a shift in profitability[4] - Net income for the three months ended December 31, 2025, was $5.334 million, compared to a loss of $100.710 million for the twelve months ended December 31, 2024[13] - Adjusted EBITDA for the three months ended December 31, 2025, was $10.058 million, an increase from $12.980 million for the same period in 2024[13] Debt and Expenses - The company reduced outstanding debt by 12% during Q4 2025, with a $13.0 million principal repayment, and achieved a leverage reduction from 4.5x to 1.89x[4] - Interest expense for the twelve months ended December 31, 2025, was $11.358 million, down from $14.668 million in 2024[13] - Depreciation and amortization for the twelve months ended December 31, 2025, totaled $8.887 million, compared to $9.692 million in 2024[13] - Stock-based compensation for the twelve months ended December 31, 2025, was $485 thousand, significantly lower than $2.425 million in 2024[13] - Employee restructuring payments for the twelve months ended December 31, 2025, amounted to $1.344 million, compared to $5.776 million in 2024[13] - The company reported a loss on impairment of assets of $1.198 million for the twelve months ended December 31, 2025[13] Strategic Initiatives - The launch of the Encore AI platform aims to unify first-party data across 40+ brands to enhance commerce outcomes[8] - The company completed the acquisition and relaunch of ShopHQ, transforming it into a high-margin, drop-ship commerce platform[8] - Non-advertising revenue streams grew triple-digits year-over-year, reducing reliance on external traffic sources[8] Future Outlook - The company anticipates future revenues and income from continuing operations, along with cost reductions and market growth[14] - Forward-looking statements indicate potential product introductions and expansion plans, with a focus on capital requirements[14] - The company cautions that actual future results may differ materially from forward-looking statements due to various risks and uncertainties[15]

Company Overview - Expion360 focuses on the design, manufacturing, and sale of lithium iron phosphate (LiFePO4) batteries for RV, marine, and industrial applications, with a strong emphasis on innovative and high-density battery solutions [21]. - The company operates as one reportable business segment, focusing on Energy Storage (ES) products for RV, marine, and industrial applications [174]. - The company launched its e360 product line in December 2020, which has gained adoption among customers transitioning from lead-acid systems, and has expanded its product portfolio to include next-generation lithium battery models [23]. Market Insights - The global RV market was valued at approximately $60.7 billion in 2022 and is projected to grow at a CAGR of 11.5%, reaching an estimated $144.55 billion by 2031, driven by the transition to lithium-based battery systems [27]. - The company has added several new distributors and OEM customers in the RV and marine markets, contributing to incremental order volume during 2025 [180]. Product Development and Innovation - Expion360's lithium-ion batteries offer superior capacity, with an expected lifespan of approximately 12 years and three times the power of typical lead-acid batteries, while being half the weight [32]. - In 2024, Expion360 introduced next-generation 12V GC2 and Group 27 series LiFePO4 batteries, incorporating higher amp-hour cell options and advanced technologies like Bluetooth and CANBus communication [35]. - Research and development efforts focus on enhancing LiFePO4 battery systems, including battery management systems and thermal management, to meet evolving customer requirements [187]. - The company continues to evaluate emerging technologies, including advancements in cell chemistry and AI applications, to enhance product design and operational efficiency [189]. Financial Performance - Revenue increased by 71.6% in the year ended December 31, 2025, driven by expanded distribution relationships and increased adoption of LiFePO4 battery platforms [179]. - Net sales for the year ended December 31, 2025, increased by $4.0 million, or 71.6%, to $9.7 million compared to $5.6 million in 2024, driven by customer base expansion and increased sales to key customers [203]. - The net loss for the year ended December 31, 2025, was $6.2 million, a reduction from $13.5 million in 2024, attributed to increased net sales and improved gross margins [211]. Cost Structure and Supply Chain - Raw material costs account for over 50% of the company's cost of goods sold, with lithium pricing being a key factor affecting battery cell costs [182]. - The company relies on third-party manufacturers located in Asia for battery production, which exposes it to risks related to raw material availability and pricing [73]. - The company experienced supply chain disruptions and component shortages in the past, which could negatively impact future operations and financial results [79]. Customer Concentration and Risks - The company currently has around 300 customers, with four customers accounting for approximately 60% of gross sales during the year ended December 31, 2025 [46][47]. - The company has a substantial customer concentration, with a limited number of customers accounting for a significant portion of sales in 2025 and 2024 [63]. - Sales to four customers accounted for approximately 60% of gross sales in 2025, indicating significant customer concentration risks [81]. Regulatory and Compliance - The company’s batteries have achieved UL 1973 certification as of December 31, 2025, ensuring compliance with safety standards [51]. - The company is subject to extensive and changing environmental regulations, which could impose costly compliance requirements and affect operational capabilities [99]. Operational Challenges - The company has experienced recurring losses and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern [72]. - The company is vulnerable to attrition among senior management, which could adversely affect its business and financial condition [113]. - The company is addressing cash flow challenges by raising additional capital and managing operational expenses [216]. Future Outlook - The company intends to continue investing in sales and marketing, product development, and research and development to drive long-term growth [70]. - Future growth depends on the ability to accurately predict customer demand, which is influenced by various economic factors [80]. - The company expects to continue incurring additional losses and may need to raise additional debt or equity financing to support market expansion and product development [216]. Cybersecurity and Data Management - The company has a cybersecurity risk management program in place to protect its information systems against operational risks related to cybersecurity [146]. - There is a risk of data breaches and cyberattacks that could adversely affect the company's reputation and operational results [108]. Shareholder Considerations - The company does not anticipate paying dividends on its common stock in the foreseeable future, focusing instead on retaining earnings for business operations and debt repayment [118]. - The company may need to raise additional funds through new equity securities or debt, which could dilute existing stockholders [110].

Financial Performance and Funding - As of December 31, 2025, the company has accumulated losses of $120,436 thousand and generated losses of $15,057 thousand for the year ended December 31, 2025[49]. - The company expects to continue incurring significant operating losses and will primarily fund operations through current financial resources, product sales, and additional equity or debt financing[49]. - The current cash and cash equivalents position of approximately $8.9 million is insufficient to fund planned operations for at least the next 12 months[64]. - The company may need to raise substantial additional funding to continue operations, which may not be available on acceptable terms[64]. - The global economy has experienced extreme volatility, impacting liquidity, consumer confidence, and economic growth, which may adversely affect the company's financial condition and share price[69]. - The company anticipates incurring costs associated with operating as a public company, estimated at least $1 million annually[56]. - Future revenues will depend on market acceptance, competition, pricing, and reimbursement from third-party payors for the ProSense and XSense systems[58]. Regulatory Approvals and Compliance - The company has received regulatory approval for the ProSense system for treating low-risk breast cancer in women aged 70 and above, but significant revenue generation remains a challenge[59]. - The company plans to seek additional regulatory approvals to expand the market for its products, which may incur significant costs[60]. - The company has received FDA De Novo authorization for ProSense for low-risk breast cancer, but market penetration may be slower than anticipated, affecting revenue and financial results[74]. - The XSense system has received FDA 510(k) clearance but lacks marketing authorization for breast cancer treatment, which could limit the addressable market and impact financial performance[75]. - Regulatory changes and potential disruptions at the FDA could delay the approval and commercialization of new products, negatively impacting business operations[104]. - The company must comply with EU Medical Devices Directive and Medical Device Regulations to sell products in the European Economic Area, requiring a conformity assessment procedure[140]. - The FDA granted marketing authorization for the ProSense system for low-risk breast cancer treatment in women aged 70 and above, requiring a post-market surveillance study[154]. Market and Competition - The company is highly dependent on the successful development and commercialization of its ProSense and XSense systems, with the transition to XSense being critical as ProSense components approach end-of-life[71]. - The company faces intense competition in the medical device market, particularly from major players like Boston Scientific Corporation and Siemens Healthineers, which could limit market share and sales opportunities[109]. - The company may encounter significant competition from other firms with greater resources, which could affect market share and profitability[85]. - The success of the company's customer acquisition strategy is crucial; failure to attract or retain customers could significantly harm revenue and financial results[86]. Operational Risks - The company faces risks related to supply chain issues, as certain components for ProSense are nearing end-of-life and may not be available from multiple suppliers, potentially increasing manufacturing costs[76]. - The company may not be able to replace manufacturing capabilities in a timely manner if disruptions occur, which could lead to long-term loss of sales and profits[91]. - The company relies on third-party service providers for critical components and services, which could adversely affect product quality and business operations if these providers fail to maintain high standards[92]. - The company relies on Terumo Corporation for distribution and regulatory approvals in Japan; any failure in this relationship could adversely affect sales prospects[77][80]. Legal and Litigation Risks - The company faces potential litigation risks, including class actions, which could negatively impact financial results and divert management resources[117]. - Product liability claims and recalls pose financial risks, with the medical device industry being historically litigious[118]. - The company may face substantial penalties if unable to comply with federal and state healthcare fraud and abuse laws, including the Anti-Kickback Statute and the False Claims Act[171]. - The medical device industry is under heightened scrutiny, with potential civil and criminal penalties for violations of governmental regulations, which could adversely affect financial results[174]. Human Resources and Staffing - At the end of 2025, the company had 67 full-time employees and two part-time employees, indicating a lean staffing model that may hinder growth if additional skilled personnel cannot be recruited[105]. - The company’s ability to attract and retain skilled personnel is critical for executing its business model, with intense competition for qualified individuals in the medical device field[93]. Intellectual Property and Innovation - The company relies on patent rights and trade secrets for competitive advantage, and failure to protect these could harm its market position[198]. - Third-party intellectual property claims may delay product development and commercialization efforts[206]. - The company faces risks related to potential infringement of third-party patents, which could result in costly litigation or redesigns of products[207]. - Changes in patent laws could increase uncertainties and costs related to patent applications and enforcement, potentially adversely affecting the company's business and financial condition[210]. Economic and Market Conditions - Changes in economic conditions could adversely affect customer spending and the company's financial condition, impacting revenue and growth prospects[124]. - The implementation of volume-based procurement policies in China could lead to reduced margins and necessitate renegotiation of distributor arrangements[102]. - The company is subject to strict price controls in non-U.S. markets, which may adversely affect profitability and revenue generation[101]. Data Privacy and Cybersecurity - Compliance with U.S. data protection laws, including the California Consumer Privacy Act (CCPA), may increase compliance costs and potential liability for the company[176]. - The company expects to collect and process sensitive health information, which raises privacy and data protection concerns that could negatively impact operations[175]. - Cybersecurity breaches could disrupt operations and lead to significant costs, impacting product development and regulatory approval efforts[120]. ESG and Corporate Governance - Environmental, social, and corporate governance (ESG) issues are increasingly important to stakeholders and may affect the company's reputation and financial condition[195]. - Failure to adapt to new ESG regulations could lead to decreased investor confidence and customer demand[197]. Shareholder and Market Dynamics - Approximately 48.0% of the company's Ordinary Shares are beneficially owned by principal shareholders, officers, and directors, allowing them significant control over shareholder matters[223]. - The company has never paid cash dividends and does not anticipate doing so in the foreseeable future, which may affect investor expectations[226]. - Future sales or issuances of Ordinary Shares could depress the market price, making it difficult for the company to raise funds through equity sales[221]. - The market price of the company's Ordinary Shares may be highly volatile, influenced by various factors including clinical trial results and regulatory approvals[219].

Financial Performance - Kalaris reported a net loss of $43.4 million for the year ended December 31, 2025, a significant improvement from a net loss of $69.2 million in 2024[10]. - Total operating expenses for 2025 were $46.2 million, down from $51.7 million in 2024[16]. Cash and Funding - Cash, cash equivalents, and marketable securities totaled $118.0 million as of December 31, 2025, up from $1.6 million at the end of 2024, expected to fund operations into Q4 2027[7]. - Kalaris completed an oversubscribed private placement raising $50.0 million in December 2025[6]. Research and Development - Research and development expenses decreased to $30.8 million in 2025 from $45.0 million in 2024, primarily due to a $32.0 million royalty obligation in 2024[8]. - The company intends to initiate Phase 3 clinical trials for TH103 by the end of 2027, following preliminary data from the ongoing Phase 1b/2 study expected in 1H 2027[1]. - Positive initial data from the Phase 1a study of TH103 showed a mean 10-letter improvement in best corrected visual acuity and a mean 129µm reduction in central subfield thickness[5]. - The Phase 1a study demonstrated no dose-limiting toxicities or serious adverse events, supporting further dose escalation for TH103[4]. Administrative Expenses - General and administrative expenses increased to $15.4 million in 2025 from $6.7 million in 2024, driven by higher insurance, legal, and professional fees[9]. Share Information - The total number of shares outstanding as of December 31, 2025, was 22,902,418[10].

Financial Performance - Fourth quarter net sales increased by 2.5% to $1,718.5 million, while full year net sales grew by 2.0% to $6,053.4 million[3][4] - Fourth quarter comparable sales declined by 1.6%, and full year comparable sales decreased by 1.5%[3][4] - Fourth quarter diluted GAAP EPS was $1.98, reflecting a 4.8% increase year-over-year[3] - Net sales for the fiscal year ended January 31, 2026, reached $6,053,414, an increase from $5,933,450 for the previous year, representing a growth of 2.0%[26] - Gross margin improved to 34.8% for the fiscal year ended January 31, 2026, compared to 33.9% in the prior year[26] - Operating income for the fiscal year ended January 31, 2026, was $512,184, a decrease from $538,639 in the previous year, reflecting an operating margin of 8.5%[26] - Net income for the fiscal year ended January 31, 2026, was $376,768, down from $418,447 the previous year, resulting in a net income margin of 6.2%[26] - Adjusted Net Income for the fiscal year ended January 31, 2026, was $393.183 million, down from $439.487 million in the previous year[36] Cash and Assets - The company reported a 14.3% increase in cash and cash equivalents, totaling $330.3 million as of January 31, 2026[6] - Cash and cash equivalents increased to $330,320 as of January 31, 2026, compared to $288,929 at the end of the previous fiscal year[28] - Total assets grew to $5,277,036 as of January 31, 2026, up from $4,900,963 the previous year[28] - Total liabilities increased to $3,105,659 as of January 31, 2026, compared to $2,896,928 the previous year[28] - Net cash provided by operating activities for the fiscal year ended January 31, 2026, was $434.798 million, down from $528.082 million in the previous year[40] Inventory and Store Expansion - Merchandise inventories increased by 14.9% to $1,503.8 million, with inventory per store up 6.3% in dollars[6] - The company reported a decrease in merchandise inventories to $1,503,756 as of January 31, 2026, from $1,308,840 the previous year[28] - The company opened 24 new stores in fiscal 2025 and plans to open an additional 20-25 stores in fiscal 2026[9] - The company plans to continue expanding its market presence and opening new stores as part of its strategic growth initiatives[21] Future Guidance - For fiscal 2026, the company expects net sales to range from $6,175 million to $6,355 million, representing a growth of 2.0% to 5.0%[12] - The guidance for fiscal 2026 includes an expected GAAP net income of $380 million to $415 million, a 5.6% increase compared to fiscal 2025[12] - The company projects Adjusted Net Income for the fiscal year ending January 30, 2027, to be between $410.0 million and $445.0 million[38] - The guidance for Diluted Adjusted Earnings per Common Share for the fiscal year ending January 30, 2027, is expected to range from $6.10 to $6.60[38] Dividends and Share Repurchase - The quarterly dividend was increased by 15% per share, marking the fourth consecutive year of growth[8] - The company has approximately $437 million remaining on its current share repurchase authorization as of the end of fiscal 2025[11] Adjusted Metrics - Adjusted EBITDA for the fiscal quarter ended January 31, 2026, was $202.571 million, compared to $211.665 million for the previous quarter[33] - Adjusted Earnings per Common Share, Diluted, for the fiscal quarter ended January 31, 2026, was $1.97, compared to $1.96 in the previous quarter[36] - Adjusted Free Cash Flow for the fiscal quarter ended January 31, 2026, was $143.724 million, significantly higher than $90.494 million in the previous quarter[40] Risks and Challenges - Future performance is subject to various risks, including macroeconomic challenges and changes in consumer spending patterns[21] - The company incurred $30.0 million in equity compensation adjustments for the fiscal year ending January 30, 2027[38]

Financial Performance - For the year ended December 31, 2025, Neuronetics generated revenues of $149.2 million, representing a 99% increase compared to the previous year[27]. - U.S. revenues for the same period were $146.0 million, a 101% increase from $72.5 million in 2024, with clinic revenues accounting for 59% of U.S. revenues[28]. - The company incurred net losses of $39.1 million and $43.7 million for the years ended December 31, 2025 and 2024, respectively, resulting in an accumulated deficit of $458.8 million as of December 31, 2025[118]. - The company reported approximately $1.3 million in reimbursements that may be subject to recoupment due to audits by Medicare Administrative Contractors[209]. - The company has faced challenges in billing for healthcare services, which could negatively impact revenue and cash flow[208]. Market Opportunity - The total annual addressable market opportunity for treatment sessions in the U.S. is estimated to be approximately $8.9 billion, based on the number of patients eligible for NeuroStar Advanced Therapy[18]. - The total annual addressable market opportunity for treatment sessions in the United States is approximately $8.9 billion, targeting 13.9 million patients with major depressive disorder (MDD) who are currently treated in various practices[39]. - Approximately 6.4 million patients have failed to achieve remission from prior antidepressant therapy, with about 3.8 million having coverage for the NeuroStar Advanced Therapy System[39]. - The company targets approximately 53,000 psychiatrists across 26,000 psychiatric practices, focusing on those that accept commercial insurance and Medicare[43]. Product and Technology - The NeuroStar Advanced Therapy System has treated an estimated 237,574 global patients with over 8.5 million treatment sessions through December 31, 2025[16]. - The response and remission rates for patients treated with NeuroStar therapy were reported at 68% and 45% respectively at 12 months, based on a clinical study[24]. - The company plans to enhance the NeuroStar Advanced Therapy System and develop additional indications for neurohealth disorders[44]. - The patent estate includes 62 issued or allowed patents and 17 pending applications related to the NeuroStar Advanced Therapy System as of December 31, 2025[54]. Regulatory Environment - The FDA's 510(k) clearance process typically takes between 30 to 90 days, but may extend up to an additional 180 days if more information is required[69]. - A PMA application requires extensive technical, preclinical, and clinical data to demonstrate safety and effectiveness, with a review period of approximately 180 days[71][72]. - The company is subject to compliance with various federal laws, including the Anti-Kickback Statute and the False Claims Act, which impose significant penalties for violations, including treble damages and mandatory penalties ranging from $14,308 to $28,619 per false claim[89]. - The company is required to comply with HIPAA and HITECH regulations, which impose strict privacy and security obligations regarding health information[88]. Operational Challenges - The company is experiencing challenges in attracting and retaining skilled personnel, which could negatively impact its operations and growth[149]. - The anticipated growth may strain the company's operational infrastructure, including supply chain and customer service[160]. - The company must adequately train providers on the use of its products to achieve expected growth, which requires significant time and resources[134]. - The integration with Greenbrook may be more difficult and costly than expected, potentially affecting anticipated revenue and cost synergies[201]. Competitive Landscape - The company operates in a competitive environment, and failure to effectively promote and sell its products could significantly decrease sales[119]. - The company faces intense competition from other TMS therapy providers, which may impact its sales and operating results[141]. - The company faces significant competition from pharmaceutical companies and lower-cost competitors, necessitating continuous innovation[153]. International Expansion - Neuronetics is expanding its commercialization efforts in the U.S. and pursuing international opportunities, particularly in Japan, which has the third largest healthcare spend globally[25]. - The approval process for the NeuroStar Advanced Therapy System in Japan follows the Shonin process for Class III devices, which can take between two to twelve months[99]. - The company currently sells products in five countries outside the U.S. and is exploring further international market expansion[166]. - The company is subject to varying reimbursement systems in international markets, which could hinder international sales growth[131]. Compliance and Legal Risks - The company must comply with Nasdaq's continued listing requirements, including a minimum bid price of $1.00 per share, which it temporarily failed to meet in October 2024[205]. - Failure to comply with healthcare regulations could result in fines, penalties, and sanctions, adversely affecting operations[214]. - The complexity of billing and reimbursement processes may lead to increased carrying costs and potential bad debt expenses[212]. - The company may incur substantial costs and reputational harm if employees or partners engage in misconduct or regulatory violations[172]. Strategic Initiatives - The company intends to roll out the Better Me Provider Program to all 93 Treatment Centers to optimize operations and increase the number of centers offering SPRAVATO[52]. - The company is exploring new purchasing models, including capital-only purchases and lease options for the NeuroStar Advanced Therapy System[44]. - The company is making substantial investments in IT systems, including potential adoption of generative AI, which may pose integration risks[184]. - The company may pursue growth through acquisitions or investments, which involve risks related to integration and management[193][194].

Revenue Performance - For the three months ended January 31, 2026, total revenues increased by 121.89% to $1,383,941 compared to $623,709 for the same period in 2025[168]. - The company generated $1,000,000 from sales of recyclable e-waste materials, which accounted for 72.26% of total revenues for the quarter[168]. - Revenues for the three months ended January 31, 2026, were $1,383,941, an increase of $760,232 or 121.89% compared to $623,709 for the same period in 2025, primarily driven by increased sales of recyclable e-waste materials[179]. - Revenue from sales of recyclable materials accounted for 68.08% of total revenues for the nine months ended January 31, 2026, with an increase of $1,000,000 from nil in 2025[197]. - Revenues for the nine months ended January 31, 2026, were $1,468,941, an increase of $708,358 or 93.13% compared to $760,583 for the same period in 2025[204]. - The increase in revenues was primarily attributed to increased sales of recyclable e-waste materials by $1,000,000, partially offset by decreased sales in food imports and consulting services[204]. Cost and Expenses - Total cost of revenues increased by 243.01% to $1,300,286 for the three months ended January 31, 2026, compared to $379,081 in 2025[174]. - Cost of revenues for the three months ended January 31, 2026, was $1,300,286, a significant increase of $921,205 or 243.01% from $379,081 in 2025, mainly due to the new operating segment of recyclable e-waste materials[182]. - General and administrative expenses rose to $635,248 for the three months ended January 31, 2026, an increase of $500,425 or 371.17% from $134,823 in 2025, largely due to higher professional fees and increased insurance expenses[187]. - Selling expenses surged to $1,314,182, an increase of $1,227,844 or 1,422.14% from $86,338 in 2025, primarily due to increased advertising and marketing expenses[211]. - General and administrative expenses rose to $2,388,059, reflecting an increase of $1,445,485 or 153.36% compared to $942,574 in 2025, driven by higher professional fees and rent expenses[212]. Profitability - Gross profit for the three months ended January 31, 2026, was $83,655, a decrease of $160,973 or 65.80% compared to $244,628 in 2025, with a gross margin of 6.04% versus 39.22% in the prior year[185]. - The gross profit margin for the sale of food and beverage dropped to 5.02% in 2026 from 40.37% in 2025, indicating significant challenges in this segment[185]. - Gross profit decreased to $168,603 for the nine months ended January 31, 2026, a decline of $163,618 or 49.25% from $332,221 in 2025, with a gross margin of 11.48% compared to 43.68% in 2025[210]. Net Loss - Net loss from continuing operations for the three months ended January 31, 2026, was $548,336, compared to a net income of $80,226 in 2025, representing an increase in net loss of $628,562 or 783.49%[190]. - Net loss from continuing operations was $3,517,720 for the nine months ended January 31, 2026, compared to a loss of $703,642 in 2025, representing an increase of $2,814,078 or 399.93%[215]. - Net loss for the nine months ended January 31, 2026, was $4,164,376, an increase of $3,744,894 or 892.74% from a loss of $419,482 in 2025[217]. Cash Flow and Liquidity - The company had a cash balance of approximately $0.30 million and accounts receivable of approximately $0.22 million as of January 31, 2026[219]. - The company reported a net loss from continuing operations of approximately $3.52 million for the nine months ended January 31, 2026, and a cash outflow from operating activities of approximately $1.30 million during the same period[221]. - Net cash used in operating activities from continuing operations increased by $254,275 compared to the same period in 2025, primarily due to an increased net loss and higher outstanding accounts receivable[225]. - Net cash used in investing activities from continuing operations was $880,000 for the nine months ended January 31, 2026, compared to nil for the same period in 2025, mainly due to loans made to Bio Essence Pharmaceutical and Valemi Inc.[227]. - Net cash provided by financing activities from continuing operations was $1,607,213 for the nine months ended January 31, 2026, compared to a net cash outflow of $14,289 for the same period in 2025[229]. - As of January 31, 2026, the company's working capital was approximately $2.15 million, with plans to improve liquidity through operational cash flows, debt financing, and potential equity financing[220]. Market Strategy - The company has temporarily paused certain imports from China and is pursuing alternative sourcing strategies to mitigate risks associated with trade policies[158]. - The company is actively working with Costco and other retailers to introduce new products that are less sensitive to tariff tensions between the U.S. and China[158]. - The company plans to diversify its markets from major mass market channels to ethnic supermarket chains to increase revenue[170]. - The company plans to diversify its markets from major mass market channels to ethnic supermarket chains to increase revenue from its FuAn brand[221]. - The company is actively developing relationships with potential customers in the United States for its recyclable e-waste materials sales[242]. Regulatory and Accounting Matters - The Company follows FASB ASC Topic 740 for tax position recognition and measurement, which includes evaluating the likelihood of sustaining a tax position on audit[245]. - The Company utilizes a two-step approach for uncertain income tax positions, measuring tax benefits based on a more than 50% likelihood of realization[246]. - The Company is evaluating the impact of ASU 2024-03, which requires detailed disclosures about expenses, effective for annual reporting periods beginning after December 15, 2026[249]. - ASU 2025-01, issued in January 2025, addresses expense disaggregation disclosures, effective for annual reporting periods beginning after December 15, 2026[250]. - The Company does not expect the adoption of ASU 2025-03 regarding business combinations to materially impact its financial position or results of operations[252]. - The Company is currently evaluating the impact of ASU 2025-04 on stock compensation and revenue recognition, effective for annual reporting periods beginning after December 15, 2026[253]. - The Company is assessing the implications of ASU 2025-05 on credit loss measurement for accounts receivable, effective for annual reporting periods beginning after December 15, 2025[254]. - Management believes that no other recently issued guidance will materially impact the Company's financial statement presentation or disclosures[255]. - The Company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[257]. Concerns and Risks - The company has a substantial doubt about its ability to continue as a going concern for the next 12 months due to potential cash resource needs for investments or acquisitions[222].